FDA: Capricor's Duchenne Drug Failed Phase 3 Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA said Monday that Capricor Therapeutics' deramiocel did not meet the objectives of a Phase 3 trial, directly contradicting the company's December announcement that the drug met both primary and secondary endpoints in a large, randomized study.
- Capricor reported in December that deramiocel preserved upper-arm function and delayed the heart failure most Duchenne patients eventually experience — the same endpoints the FDA is now disputing.
- Deramiocel was tested primarily in teenagers and young men who had already lost the ability to walk, a population the source flags as having few treatment options despite immense advances in genetic medicine.
- Duchenne muscular dystrophy remains a fatal childhood disease that has proven stubbornly difficult to treat, making any efficacy dispute especially high-stakes for patients and families.
- The FDA's negative assessment lands ahead of an advisory committee hearing on the drug, putting the agency's doubts on the table before outside experts weigh in.
Why it matters: An FDA briefing that questions efficacy right before an advisory committee hearing increases the risk that the panel votes against recommending deramiocel, potentially denying Duchenne patients who have already lost ambulation a treatment the company says preserved arm and cardiac function. For Capricor, the public contradiction of its December endpoint claims damages credibility on its lead Duchenne asset ahead of a decision that will shape its near-term value.
